Nichol L. Ochsner
Vice President of Investor Relations & Corporate CommunicationsMs. Nichol L. Ochsner is Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.) since August 2022. She was Vice President of Investor Relations of TherapeuticsMD since 2018. Ms. Ochsner serves as Executive Director of Investor Relations & Corporate Communications at POZEN Inc. She served as Executive Vice President of Investor Relations and Corporate Communications at Statera Biopharma, Inc. (formerly known as Cytocom, Inc.) since July 2021 until August 2022. Ms. Ochsner joined Statera Biopharma, Inc. since July 2021. Ms. Ochsner served as Senior Director of Investor Relations at Auxilium Pharmaceuticals Inc. She was Executive Director, Investor Relations and Corporate Communications at Aralez Pharmaceuticals., and Ms. Ochsner also held positions at Auxilum, Medarex, Kos Pharmaceuticals, Genta, Enzon Pharmaceuticals and AXA Financial. She is a Member of National Investor Relations Institute (NIRI) and holds a B.A. in Pre-Law from West Virginia University.
Positions
- Company NameZevra Therapeutics, Inc.Stock CodeZVRAPositionVice President of Investor Relations & Corporate CommunicationsColleagues
- NFNeil F. McFarlanePresident, CEO & Director
- TATamara A. FavoritoIndependent Chair
- RWRahsaan W. ThompsonChief Legal Officer, Secretary & Compliance Officer
- JAJustin A. RenzCFO & Treasurer
- APAlison PetersChief People Officer
- BBBarney BishopChairman of Scientific and Medical Advisory Board
- JAJeffrey A. GudinCo-Chair of Physician Advisory Council
- SNSrinivas NalamachuCo-Chair of Physician Advisory Council
